162 related articles for article (PubMed ID: 34714596)
21. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
[TBL] [Abstract][Full Text] [Related]
22. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
[TBL] [Abstract][Full Text] [Related]
23. Identification of Hypoxia-inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control.
Mathew B; Philip M; Perwad Z; Karatt TK; Caveney MR; Subhahar MB; Karakka Kal AK
Drug Test Anal; 2021 Jun; 13(6):1203-1215. PubMed ID: 33569900
[TBL] [Abstract][Full Text] [Related]
24. Desidustat: First Approval.
Dhillon S
Drugs; 2022 Jul; 82(11):1207-1212. PubMed ID: 35834123
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Gupta N; Wish JB
Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
[TBL] [Abstract][Full Text] [Related]
26. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
Joharapurkar AA; Pandya VB; Patel VJ; Desai RC; Jain MR
J Med Chem; 2018 Aug; 61(16):6964-6982. PubMed ID: 29712435
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function.
Mahar KM; Shaddinger BC; Ramanjineyulu B; Andrews S; Caltabiano S; Lindsay AC; Cobitz AR
Clin Pharmacol Drug Dev; 2022 May; 11(5):562-575. PubMed ID: 35355447
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure.
Yazaki M; Nabeta T; Takigami Y; Eda Y; Fujita T; Iida Y; Ikeda Y; Ishii S; Ako J
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256345
[No Abstract] [Full Text] [Related]
29. lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.
Eichner D; Van Wagoner RM; Brenner M; Chou J; Leigh S; Wright LR; Flippin LA; Martinelli M; Krug O; Schänzer W; Thevis M
Drug Test Anal; 2017 Nov; 9(11-12):1768-1778. PubMed ID: 28378453
[TBL] [Abstract][Full Text] [Related]
30. Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis.
Chen D; Niu Y; Liu F; Yang Y; Wang X; Li P; Chen X
Front Pharmacol; 2023; 14():1163908. PubMed ID: 37292157
[No Abstract] [Full Text] [Related]
31. Generic approach for the discovery of drug metabolites in horses based on data-dependent acquisition by liquid chromatography high-resolution mass spectrometry and its applications to pharmacokinetic study of daprodustat.
Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Sato F; Kuroda T; Yamada M; Leung GN
Anal Bioanal Chem; 2022 Nov; 414(28):8125-8142. PubMed ID: 36181513
[TBL] [Abstract][Full Text] [Related]
32. Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases.
Miao M; Wu M; Li Y; Zhang L; Jin Q; Fan J; Xu X; Gu R; Hao H; Zhang A; Jia Z
Front Pharmacol; 2022; 13():837249. PubMed ID: 35281917
[TBL] [Abstract][Full Text] [Related]
33. Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Patel H; Modi N; Chaudhari J; Patel P; Giri P; Patel H; Pandya V; Desai R; Jain M
Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):725-740. PubMed ID: 35881329
[TBL] [Abstract][Full Text] [Related]
34. Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry.
Hansson A; Thevis M; Cox H; Miller G; Eichner D; Bondesson U; Hedeland M
J Pharm Biomed Anal; 2017 Feb; 134():228-236. PubMed ID: 27918992
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
[TBL] [Abstract][Full Text] [Related]
37. Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination.
Mahar KM; Caltabiano S; Andrews S; Ramanjineyulu B; Chen L; Young G; Pereira A; Lindsay AC; van den Berg F; Cobitz AR
Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1419-1431. PubMed ID: 34713596
[TBL] [Abstract][Full Text] [Related]
38. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
[TBL] [Abstract][Full Text] [Related]
39. Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren.
Philip M; Karakka Kal AK; Subhahar MB; Perwad Z; Karatt TK
Rapid Commun Mass Spectrom; 2021 Dec; 35(23):e9201. PubMed ID: 34542924
[TBL] [Abstract][Full Text] [Related]
40. A computational evaluation of FDA medicines' ability to inhibit hypoxia-inducible factor prolyl hydroxylase-2 (PHD-2) for acute respiratory distress syndrome.
Chandrasekaran J; Balasubramaniam J
Struct Chem; 2022; 33(5):1391-1407. PubMed ID: 35855326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
